References

All references link to appropriate papers

1.

EMC. Xaluprine 20 mg/ml oral suspension – Summary Of Product Characteristics (SmPC) [Internet] 2023. Available from: https://www.medicines.org.uk/emc/product/2949/ Accessed March 2024

2.

EMA. Xaluprine (previously Mercaptopurine Nova Laboratories) [Internet] 2012. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/xaluprine Accessed March 2024

3.

Scottish Medicines Consortium. mercaptopurine (Xaluprine) [Internet] 2012. Available from: https://www.scottishmedicines.org.uk/medicines-advice/mercaptopurine-xaluprine-abbreviatedsubmission-79812/ Accessed March 2024

4.

All Wales Medicines Strategy Group. Mercaptopurine (Xaluprine®) 20 mg/ml oral suspension [Internet] 2012. Available from: https://www.crd.york.ac.uk/crdweb/ShowRecord.asp?LinkFrom=OAI&ID=32012000875&LinkFrom=OAI&ID=32012000875 Accessed March 2024

5.

Mulla H, Leary A, White P, Pandya HC. A step toward more accurate dosing for mercaptopurine in childhood acute lymphoblastic leukemia. J Clin Pharmacol. 2012;52(10):1610–3.

6.

Breitkreutz J, Boos J. Paediatric and geriatric drug delivery. Expert Opin Drug Deliv. 2007;4(1):37–45.

7.

Mulla H, Buck H, Price L, Parry A, Bell G, Skinner R. “Acceptability” of a new oral suspension formulation of mercaptopurine in children with acute lymphoblastic leukaemia. J Oncol Pharm Pract. 2015 ;22(3):387–95.

8.

Batchelor HK, Marriott JF. Formulations for children: Problems and solutions. Br J Clin Pharmacol. 2015;79(3):405–18

9.

EMA. Formulations of choice for the paediatric population – Scientific guideline [Internet] 2006. Available from: https://www.ema.europa.eu/en/formulations-choice-paediatric-population#document-history—first-version-(current)-section Accessed March 2024

10.

Bhatia S, Landier W, Hageman L, Chen Y, Kim H, Sun CL, et al. Systemic exposure to thiopurines and risk of relapse in children with acute lymphoblastic leukemia: A children’s oncology group study. JAMA Oncol. 2015 ;1(3):287–95.

11.

Venables R, Batchelor H, Hodson J, Stirling H, Marriott J. Determination of formulation factors that affect oral medicines acceptability in a domiciliary paediatric population. Int J Pharm. 2015 ;480(1–2):55–62.

12.

Bhatia S, Landier W, Shangguan M, Hageman L, Schaible AN, Carter AR, et al. Nonadherence to Oral Mercaptopurine and Risk of Relapse in Hispanic and Non-Hispanic White Children With Acute Lymphoblastic Leukemia: A Report From the Children’s Oncology Group. J Clin Oncol. 2012;30(17):2094-2101.

13.

Hande KR. Purine Antimetabolites. In Cancer Chemotherapy & Biotherapy: Principles & Practices, 4th Edition [Internet] 2002. Available from: https://doctorlib.info/oncology/biotherapy/9.html Accessed March 2024

14.

ALLTogether1 – A Treatment study protocol of the ALLTogether Consortium for children and young adults (1-45 years of age) with newly diagnosed acute lymphoblastic leukaemia (ALL). v1.4. 09 Sep 2020.

15.

Schrappe M, Reiter A, Zimmermann M, Harbott J, Ludwig W-D, Henze G, et al. Long-term results of four consecutive trials in childhood ALL performed by the ALL-BFM study group from 1981 to 1995. Leukemia. 2000;14(12):2205–22.